PharmRep Direct from the editors of Pharmaceutical Representative

February 4, 2011 Issue 49 Vol. 2	www.pharmrep.com
Contact Editor: Reid Paul

To confirm your subscription, click here
In order to ensure future delivery of email newsletters from Pharmaceutical Representative please take a moment to confirm your subscription by
clicking here.

Thank you,
Pharmaceutical Representative Staff

New Opportunity in the Absence of Avastin
In July 2010, FDA was urged to withdraw the use of Avastin in metastatic HER2-negative breast cancer. Since then, it has been dropped across all lines of therapy—but for other products in the breast cancer market, this does not necessarily open the door for new therapies
ť MORE

Fighting Cancer—A Checklist for Change
Payer and regulatory pressures are likely to take some steam off of heady projections of market growth in this sensitive therapeutic area
ť MORE

A New Business Model for Personalized Medicine
Eisai lent its support for R&D in personalized medicine with a pledge to fund a biotech
ť MORE

How Doctors Rate Reps
New data reveals that doctors are demanding more from reps and some are delivering
ť MORE

Emergency Medicine
What you need to know to sell to emergency room physicians
ť MORE

The Slow, Steep Climb
The new year presents pharma with so many unprecedenteds and unpredictables that the patent cliff may be the least of its problems
ť MORE

Pfizer closes UK research site

Politics and PDUFA

Killer apps or rep killer?

Follow Pharm Rep on Twitter

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.